# This is a Study to Evaluate the Effect of Aging of Multiple Doses of GLPG1205 in Healthy Subjects

> **NCT03102567** · PHASE1 · COMPLETED · sponsor: **Lakefront Biotherapeutics NV** · enrollment: 32 (actual)

## Conditions studied

- Healthy
- Elderly

## Interventions

- **DRUG:** GLPG1205 50mg q.d.
- **DRUG:** Placebo oral capsule
- **DRUG:** GLPG1205 250 loading dose and 50mg q.d. maintenance dose

## Key facts

- **NCT ID:** NCT03102567
- **Lead sponsor:** Lakefront Biotherapeutics NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-18
- **Primary completion:** 2017-02-13
- **Final completion:** 2017-02-13
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2017-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03102567

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03102567, "This is a Study to Evaluate the Effect of Aging of Multiple Doses of GLPG1205 in Healthy Subjects". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03102567. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*